Why the study?
Does oral rivaroxaban improve patient-reported treatment satisfaction compared to enoxaparin/VKA therapy in patients with acute symptomatic DVT without PE?
Population
1,472 patients with acute symptomatic deep-vein thrombosis without pulmonary embolism, multinational
Comparison
Rivaroxaban for up to 12 months vs Enoxaparin/vitamin K antagonist (VKA) therapy
Design
RCT, randomised, open-label
Follow-up
12 months
Authors
Loading...
May favor rivaroxaban over enoxaparin/VKA for acute DVT to improve satisfaction; RCT confirms advantages in patient-reported outcomes.
Does oral rivaroxaban improve patient-reported treatment satisfaction compared to enoxaparin/VKA therapy in patients with acute symptomatic DVT without PE?
Rivaroxaban significantly improves patient-reported treatment satisfaction and reduces perceived anticoagulation burden compared to standard enoxaparin/VKA therapy in patients with acute DVT.
Bamber et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: